ORLANDO -- Long-term results from trials of new drugs for hereditary angioedema (HAE) continue to support efficacy and safety ...

Phase 4 results from the UnlIMMited trial show that risankizumab significantly improves psoriasis (PsO) symptoms in the genital and scalp regions, achieving higher clearance rates compared ...

Developed by British drugmaker GSK, RTS,S/AS01E in 2021 became the first malaria vaccine to be recommended by the World ...

SIM0278 benefits from Simcere’s protein engineering platform, embodying mutations to decrease binding to effector T cells.

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM ESTCompany ParticipantsDave Gancarz - Chief Business ...

Using nationwide networks, advanced cytokine profiling, and patient clustering, the team screened over 100 PAH patients to ...

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

"Cogent’s stock soars on Phase III gastrointestinal cancer data" was originally created and published by Clinical Trials ...

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

Tong Dai, MD: Considering all the options, it looks like if the patient needs faster response, pembrolizumab plus lenvatinib ...